Early intervention of plasma exchange combined with intensive immunosuppressive treatment for anti-MDA-5 antibody-positive rapidly progressive interstitial pneumonia: Two case reports

被引:2
|
作者
Ishiwari, Mayuko [1 ]
Togashi, Yuki [1 ]
Takoi, Hiroyuki [1 ]
Kikuchi, Ryota [1 ]
Kawagoe, Junichiro [1 ]
Toriyama, Kazutoshi [1 ]
Tanaka, Akane [1 ]
Nagotomo, Yoko [1 ]
Kinoshita, Hayato [1 ]
Kono, Yuta [1 ]
Abe, Shinji [1 ]
机构
[1] Tokyo Med Univ Hosp, Dept Resp Med, Tokyo, Japan
关键词
Anti-MDA-5; antibody; Plasma exchange; Rapidly progressive interstitial pneumonia; LUNG-DISEASE;
D O I
10.1016/j.rmcr.2021.101464
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: Anti-melanoma differentiation-associated gene 5 antibody (anti-MDA5 Ab) has to be reported to often cause rapidly progressive interstitial lung disease (RP-ILD) especially in East Asian countries. Even with the recommended rapid administration of immunosuppressive agents with high-dose corticosteroids, intravenous pulse cyclophosphamide, and calcineurin inhibitors, the prognosis of anti-MDA5 Ab-related RP-ILD is poor. Plasma exchange (PE) has been reported to be effective for steroid-refractory RP-ILD with anti-MDA5 Ab. However, the timing, frequency, and interval of PE for the treatment of RP-ILD with anti-MDA5 Ab have not yet been established. Case presentation: We report two cases of RP-ILD with anti-MDA5 Ab treated by early intervention of PE combined with immunosuppressive treatment. Blood biomarkers including titers of anti-MDA5 Ab, serum KL-6 and ferritin were promptly decreased after each session of PE. Clinical symptoms, oxygenation and chest computed tomography abnormalities were completely improved after immunosuppressive treatment with PE. Conclusion: Early intervention of PE combined with immunosuppressive treatment may prevent the development to lethal severe respiratory failure in RP-ILD with anti-MDA5 Ab.
引用
收藏
页数:5
相关论文
共 47 条
  • [21] Anti-MDA5 positive dermatomyositis complicated with rapidly progressive interstitial lung disease - a case report
    De Backer, Eva
    Gremonprez, Felix
    Brusselle, Guy
    Depuydt, Pieter
    Van Dorpe, Jo
    Van Haverbeke, Carole
    Goeminne, Pieter C.
    Derom, Eric
    ACTA CLINICA BELGICA, 2018, 73 (06) : 413 - 417
  • [22] Efficacy of plasma exchange in patients with anti-MDA5 rapidly progressive interstitial lung disease
    Bay, Pierre
    de Chambrun, Marc Pineton
    Rothstein, Vincent
    Mahevas, Matthieu
    De Prost, Nicolas
    Roux, Antoine
    Zuber, Benjamin
    Biet, Dominique Israel
    Hervier, Baptiste
    Tazi, Abdellatif
    Mouthon, Luc
    Mekinian, Arsene
    Deligny, Christophe
    Borie, Raphael
    Meurice, Jean Claude
    Meyer, Alain
    Priou, Pascaline
    Savale, Laurent
    Martin, Luc De Saint
    Gallay, Laure
    Cottin, Vincent
    Blanchard, Elodie
    Brillet, Pierre-Yves
    Khafagy, Philippe
    Benveniste, Olivier
    Nunes, Hilario
    Allenbach
    Uzunhan, Yurdaguel
    JOURNAL OF AUTOIMMUNITY, 2022, 133
  • [23] Evaluation of clinical prognostic factors for interstitial pneumonia in anti-MDA5 antibody-positive dermatomyositis patients
    Fujiki, Youhei
    Kotani, Takuya
    Isoda, Kentaro
    Ishida, Takaaki
    Shoda, Takeshi
    Yoshida, Shuzo
    Takeuchi, Tohru
    Makino, Shigeki
    MODERN RHEUMATOLOGY, 2018, 28 (01) : 133 - 140
  • [24] The Balance Between Intensive and Palliative Care in an Anti-melanoma Differentiation-Associated Gene 5 (MDA5) Antibody-Positive Acute Interstitial Pneumonia in a Nonagenarian: A Case Report
    Asano, Yuri
    Fujimori, Taichi
    Sano, Chiaki
    Ohta, Ryuichi
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (03)
  • [25] Rapidly progressive interstitial lung disease with positive anti-MDA5 antibody as an immune-related complication of nivolumab: A case report
    Kato, Sayaka
    Sakamoto, Koji
    Sato, Tomonori
    Kobayashi, Tomoko
    Shindo, Yuichiro
    Morise, Masahiro
    Iwama, Shintaro
    Arima, Hiroshi
    Ishii, Makoto
    RESPIRATORY INVESTIGATION, 2024, 62 (02) : 313 - 316
  • [26] Double anti-PL-7 and anti-MDA-5 positive Amyopathic Dermatomyositis with rapidly progressive interstitial lung disease in a Hispanic patient
    Zi Ying Li
    Evanpaul Gill
    Fan Mo
    Candice Reyes
    BMC Pulmonary Medicine, 20
  • [27] Successful tocilizumab treatment for rapidly progressive interstitial lung disease with anti-MDA5-positive juvenile dermatomyositis: a case report and literature review
    Qiu, Lingzhi
    Shao, Xiaoyan
    Ma, Le
    Fan, Zhidan
    Yu, Haiguo
    FRONTIERS IN PEDIATRICS, 2024, 12
  • [28] Radiological and Pathological Correlation in Anti-MDA5 Antibody-positive Interstitial Lung Disease: Rapidly Progressive Perilobular Opacities and Diffuse Alveolar Damage
    Chino, Haruka
    Sekine, Akimasa
    Baba, Tomohisa
    Iwasawa, Tae
    Okudela, Koji
    Takemura, Tamiko
    Itoh, Harumi
    Sato, Shinji
    Suzuki, Yasuo
    Ogura, Takashi
    INTERNAL MEDICINE, 2016, 55 (16) : 2241 - 2246
  • [29] Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis
    Gono, Takahisa
    Sato, Shinji
    Kawaguchi, Yasushi
    Kuwana, Masataka
    Hanaoka, Masanori
    Katsumata, Yasuhiro
    Takagi, Kae
    Baba, Sayumi
    Okamoto, Yuko
    Ota, Yuko
    Yamanaka, Hisashi
    RHEUMATOLOGY, 2012, 51 (09) : 1563 - 1570
  • [30] Early initiation of plasma exchange therapy for a patient with anti-MDA5 autoantibody-positive dermatomyositis developing rapidly progressive interstitial lung disease
    Sasaki, Noriko
    Ishii, Akira
    Kurabayashi, Takayoshi
    Sugiyama, Mai
    Izumi, Yuto
    Nakagome, Yoko
    Hirano, Kazuki
    Sasaki, Sho
    Kondo, Yasushi
    Nogi, Shinichi
    Nishikawa, Ayumi
    Hosono, Yuji
    Yamada, Chiho
    Sato, Shinji
    MODERN RHEUMATOLOGY CASE REPORTS, 2021, 5 (01) : 87 - 94